Insertable cardiac monitor

DEVICE3 trials

Sponsors

Timothy J. Nelson, Region Gävleborg, University of Rochester

Conditions

Ebstein AnomalyHypertrophic CardiomyopathyPersistent Atrial Fibrillation

Phase 1

Study of Autologous Bone Marrow Derived Mononuclear Cells for Treatment of Ebstein Anomaly

CompletedNCT02914171

Timothy J. NelsonEbstein Anomaly

Start: 2016-09-30End: 2021-03-18Updated: 2022-04-26

Unknown Phase

Insertable Cardiac Monitors in Hypertrophic Cardiomyopathy

Region GävleborgHypertrophic Cardiomyopathy

Start: 2017-08-16End: 2019-04-16Target: 30Updated: 2017-08-25

Hybrid Ablation Plus Medical Therapy for Persistent Atrial Fibrillation

CompletedNCT04190186

University of RochesterPersistent Atrial Fibrillation

Start: 2020-06-25End: 2024-02-15Updated: 2025-07-29

Related Papers

Cone Reconstruction for Ebstein Anomaly: Ventricular Remodeling and Preliminary Impact of Stem Cell Therapy.

2021-09-015 citations

P6575Evaluation of arrhythmias using an insertable cardiac monitor in patients with hypertrophic cardiomyopathy

European Heart Journal2019-10-01

EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic Cardiomyopathy (ELUCIDATE HCM)—rationale and design: a prospective observational study on incidence of arrhythmias in Sweden

BMJ Open2017-12-012 citations